Journal of Immunotherapy最新文献_第4页

Design of Therapeutic Vaccines Based on Antigen Epitopes of α-9 HPV E6 in Sichuan. 四川地区HPV E6 α-9抗原表位治疗性疫苗的设计

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-04-01 DOI: 10.1097/CJI.0000000000000591

Jiaoyu He, Chunlan Cheng, Yishan Ding, Ning Li, Tianjun Li, Chengyue Wang, Bo Wei, Xianping Ding

{"title":"Design of Therapeutic Vaccines Based on Antigen Epitopes of α-9 HPV E6 in Sichuan.","authors":"Jiaoyu He, Chunlan Cheng, Yishan Ding, Ning Li, Tianjun Li, Chengyue Wang, Bo Wei, Xianping Ding","doi":"10.1097/CJI.0000000000000591","DOIUrl":"10.1097/CJI.0000000000000591","url":null,"abstract":"Persistent infections with high-risk human papillomavirus (HR-HPV) are the primary cause of vaginal/cervical squamous intraepithelial neoplasia (VAIN/CIN) and cervical cancer (CC), with the prevalence of infection escalating alongside disease severity. Notably, the α-9 HPV species was responsible for 58.20% of all HR-HPV infections in our study. Given the absence of therapies to eradicate established infections, developing effective therapeutic vaccines is a critical priority. The HPV E6 oncoprotein represents an ideal target for such immunotherapies. In this study, we used a comprehensive in silico approach to identify and characterize potential T-lymphocyte epitopes from the E6 proteins of α-9 HR-HPV, which was predominant in our study cohort. Our integrated bioinformatics pipeline encompassed sequence analysis for conservation, followed by rigorous prediction of antigenicity, allergenicity, proteasomal processing, TAP transport efficiency, and immunogenicity. Through this systematic screening, we identified a panel of epitope candidates predicted to have a high potential for eliciting a robust and specific immune response. While these predictions provide a powerful theoretical foundation, it must be stressed that they constitute computational hypotheses requiring mandatory experimental validation. Our findings do not constitute functional epitopes but rather offer a prioritized, evidence-based roadmap for future laboratory investigations. This work significantly accelerates the rational design of HPV therapeutic vaccines by narrowing the focus to the most viable candidates, thereby conserving substantial time and resources in the downstream experimental verification process.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"87-97"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer. FGL1在膀胱癌免疫微环境中的免疫检查点作用

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-04-01 DOI: 10.1097/CJI.0000000000000595

Keyao Hu, Xiaocheng Ma, Lei Luo, Peng Li

{"title":"FGL1 as an Immune Checkpoint in the Immune Microenvironment of Bladder Cancer.","authors":"Keyao Hu, Xiaocheng Ma, Lei Luo, Peng Li","doi":"10.1097/CJI.0000000000000595","DOIUrl":"10.1097/CJI.0000000000000595","url":null,"abstract":"Current treatment protocols for bladder cancer (BC) do not include additional immune checkpoint targets or biomarkers that can accurately predict treatment response. Hence, it is imperative to identify more inclusive and promising candidate compounds for immune checkpoint therapy. Therefore, we sought to investigate whether Fibrinogen Like 1 (FGL1) could serve as a new immune checkpoint for bladder cancer. Cell lines overexpressing/silencing FGL1 in human BC cells (5637, HT1376) were constructed, and the regulatory effects of FGL1 on BC cells proliferation, apoptosis, and the tumor immune microenvironment were detected using experimental techniques such as western blot, immunohistochemistry, immunofluorescence, and flow cytometry in an in vivo/vitro experimental model. Silencing FGL1 inhibited BC cells proliferation, promoted BC cells apoptosis, and stimulated tumor-infiltrating lymphocytes (TILs) activation and expansion in tumor microenvironment (TME) for antitumor immunity. Meanwhile, silencing FGL1 down-regulated the expression level of Lymphocyte Activating 3 (LAG3) to inhibit tumorigenicity in xenograft tumor models. Targeting the FGL1/LAG3 signaling pathway can stimulate bladder cancer TILs activation and expansion for antitumor immunity in TME, which inhibits tumor proliferation and growth and promotes tumor apoptosis. Therefore, FGL1 can be used as a potential immune checkpoint for the treatment of BC.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"98-107"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Features, Treatment, and Prognosis of Pembrolizumab-Induced Isolated Adrenocorticotropic Hormone Deficiency. 派姆单抗诱导的孤立性促肾上腺皮质激素缺乏症的临床特征、治疗和预后。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-04-01 DOI: 10.1097/CJI.0000000000000584

Liping Peng, Ming Shu, Zhiqiang Fan, Bin Huang, Chunjiang Wang

{"title":"Clinical Features, Treatment, and Prognosis of Pembrolizumab-Induced Isolated Adrenocorticotropic Hormone Deficiency.","authors":"Liping Peng, Ming Shu, Zhiqiang Fan, Bin Huang, Chunjiang Wang","doi":"10.1097/CJI.0000000000000584","DOIUrl":"10.1097/CJI.0000000000000584","url":null,"abstract":"Abstract: To investigate the clinical characteristics of isolated adrenocorticotropic hormone deficiency (IAD) induced by pembrolizumab, and to provide reference for diagnosis and treatment. Clinical reports of pembrolizumab-induced IAD before February 28, 2025 were collected for retrospective analysis. Twenty (51.3%) women and 19 (48.7%) men entered the study, with a median age of 66 years (range: 38-85). The median time for the onset of IAD was 7.3 months (range: 2-30) after initial administration, and the median cycle was 7 cycles (range: 2-40). Fatigue (65.8%) and anorexia (52.6%) were the most common complaints. Hyponatremia (92.3%) and eosinophilia (33.3%) were the laboratory abnormalities most commonly associated with IAD. Pituitary magnetic resonance imaging (MRI) was normal in most patients (88.2%). After receiving glucocorticoid therapy, patients' symptoms improved significantly with or without pembrolizumab. Pembrolizumab-induced IAD is a rare disease that needs to be paid sufficient attention to. IAD patients have nonspecific manifestations and may be delayed in diagnosis. Further studies are needed to confirm the risk factors and prognosis of pembrolizumab-induced IAD.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"115-119"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Checkpoint Inhibitor-Induced Ureteritis and Cystitis in Patients With Lung Cancer and Uterine Malignancies: A Case Series and Literature Review. 免疫检查点抑制剂诱导的肺癌和子宫恶性肿瘤患者输尿管炎和膀胱炎：病例系列和文献综述

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-04-01 DOI: 10.1097/CJI.0000000000000581

Yu Yan, Qiqi Dou, Xuefei Wu, Xiaotong Zhang, Xiaoyan Liu, Xiaoyan Si, Li Zhang

{"title":"Immune Checkpoint Inhibitor-Induced Ureteritis and Cystitis in Patients With Lung Cancer and Uterine Malignancies: A Case Series and Literature Review.","authors":"Yu Yan, Qiqi Dou, Xuefei Wu, Xiaotong Zhang, Xiaoyan Liu, Xiaoyan Si, Li Zhang","doi":"10.1097/CJI.0000000000000581","DOIUrl":"10.1097/CJI.0000000000000581","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy across various cancers but can cause immune-related adverse events (irAEs). While common irAEs such as dermatitis, pneumonitis, and colitis are well-documented, rare events like cystitis and ureteritis remain underrecognized. We report 3 cases of ICI-induced cystitis and ureteritis. The first case involves a 67-year-old female with lung cancer who developed immune-related cystitis and ureteritis after 3 cycles of pembrolizumab, with recurrence 8 months after discontinuation. Both episodes presented with hematuria, urinary frequency, and dysuria, and were responsive to corticosteroid treatment. The second case involves a 37-year-old female with cervical cancer who developed a truncal rash, hematuria, urinary frequency, and dysuria after the first cycle of cadonilimab, a PD-1/CTLA-4 bispecific antibody. Her condition worsened with rising serum creatinine levels. Imaging revealed bladder wall thickening and ureteral dilation. Partial symptom relief followed oral corticosteroids, but complete resolution was achieved with intravesical corticosteroid irrigation. The third case describes a 35-year-old female with endometrial cancer who presented with similar urinary symptoms and flank pain after 4 cycles of pembrolizumab. Rapid creatinine elevation necessitated ureteral stent placement, which failed to alleviate symptoms. After exclusion of infectious etiologies, immune-related cystitis/ureteritis was diagnosed. Symptoms resolved with intravenous corticosteroids. This report underscores the importance of early recognition and management of rare urinary irAEs to avoid unnecessary interventions and prolonged interruption of anti-tumor therapy. It also highlights intravesical methylprednisolone as a potential treatment modality that warrants further investigation.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"108-114"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating Bulk RNA-Seq and Spatial Transcriptomics Data to Reveal Distinct Immune Escape Mechanism and Immunotherapy Based on Post-Translational Modification in Head and Neck Squamous Cell Carcinoma. 整合大量RNA-Seq和空间转录组学数据揭示头颈部鳞状细胞癌不同的免疫逃逸机制和基于翻译后修饰的免疫治疗

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-04-01 DOI: 10.1097/CJI.0000000000000588

Kai Li, Chuyi Cai, Qingmei Chen, Danhua Hu

{"title":"Integrating Bulk RNA-Seq and Spatial Transcriptomics Data to Reveal Distinct Immune Escape Mechanism and Immunotherapy Based on Post-Translational Modification in Head and Neck Squamous Cell Carcinoma.","authors":"Kai Li, Chuyi Cai, Qingmei Chen, Danhua Hu","doi":"10.1097/CJI.0000000000000588","DOIUrl":"10.1097/CJI.0000000000000588","url":null,"abstract":"Post-translational modification (PTM) plays a crucial role in head and neck squamous cell carcinoma (HNSCC) progression, and their specific prognostic implications in HNSCC have not been thoroughly investigated. TCGA-HNSCC, GSE41613, GSE42743, and GSE65858 were merged into a meta-cohort, and 21 types of PTM were generated consensus cluster. Then, WGCNA was utilized to identify module genes. Finally, a machine learning approach was used to create the PTM.score. This analysis revealed 2 distinct subtypes of PTMs, each characterized by unique molecular signatures. By integrating different categories of genes, including DEGs, prognosis-related DEGs, module genes, and PTM-related genes, 13 hub genes were identified, and a PTM.score was developed. PTM.score was rigorously validated across 4 independent external cohorts and an in-house cohort, demonstrating its reliability and potential applicability. The PTM.score serves a dual purpose in its application, as it encapsulates the essential clinical context and offers valuable insights regarding the efficacy of immunotherapy treatments. In particular, patients categorized with a high PTM.score displayed a TME that was more actively engaged, which corresponded with a poor prognosis. Furthermore, these patients demonstrated a low level of responsiveness to immunotherapy interventions. In addition, an analysis utilizing spatial transcriptomics revealed that the PTM.score was markedly expressed within the tumor cells. This novel PTM-related prognostic signature could effectively assess the prognosis and therapeutic responses of HNSCC patients, providing new perspectives for individualized treatment for the patient population.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"120-134"},"PeriodicalIF":2.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma. 勘误：靶向bcma的双特异性抗体，同时刺激nkg2d增强多发性骨髓瘤的疗效。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-02-01 Epub Date: 2026-02-10 DOI: 10.1097/CJI.0000000000000576

Yang Wang, Hui Li, Wei Xu, Mingzhu Pan, Chun Qiao, Jialing Cai, Jingjing Xu, Min Wang, Juan Zhang

引用次数: 0

Treatment With PD-1/PD-L1 Inhibitors for Kaposi Sarcoma:A Systematic Review and Meta-Analysis. PD-1/PD-L1抑制剂治疗卡波西肉瘤：系统回顾和荟萃分析

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-02-01 Epub Date: 2025-12-15 DOI: 10.1097/CJI.0000000000000593

Francisco Cezar Aquino de Moraes, Michele Kreuz, Pedro Henrique de Souza Wagner, Nayara Rozalem Moretti, Ana Luiza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Gustavo Tadeu Freitas Uchôa Matheus, Emanuele Rocha da Silva, Rommel Mario Rodríguez Burbano

{"title":"Treatment With PD-1/PD-L1 Inhibitors for Kaposi Sarcoma:A Systematic Review and Meta-Analysis.","authors":"Francisco Cezar Aquino de Moraes, Michele Kreuz, Pedro Henrique de Souza Wagner, Nayara Rozalem Moretti, Ana Luiza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Gustavo Tadeu Freitas Uchôa Matheus, Emanuele Rocha da Silva, Rommel Mario Rodríguez Burbano","doi":"10.1097/CJI.0000000000000593","DOIUrl":"10.1097/CJI.0000000000000593","url":null,"abstract":"Abstract: Kaposi Sarcoma (KS) is an angioproliferative tumor induced by human gammaherpesvirus 8 (HHV-8). For years, cytotoxic chemotherapy was the primary treatment for advanced KS, despite high toxicity and limited efficacy. Immunotherapy, particularly PD-1/PD-L1 inhibitors, has emerged as a promising option with antitumor activity and a favorable safety profile. We conducted a meta-analysis to evaluate its efficacy and safety in KS. A systematic search in Medline, Embase, Cochrane Library, and Web of Science identified single-arm trials on PD-1/PD-L1 inhibitors in KS. Outcomes were expressed as proportions with 95% CIs, heterogeneity assessed using I ², and significance set at P <0.05. Analyses were performed in RStudio 4.4.1. Five studies with 91 patients were included. Prior treatments included chemotherapy (35.0%), radiotherapy (22.3%), and interferon (9.2%). The pooled objective response rate (ORR) was 61% (95% CI: 49-72; I ²=16%), with 17% achieving complete response (CR) (95% CI: 8-31; I ²=0%), and the disease control rate (DCR) was 91% (95% CI: 81-96; I ²=0%). The most frequent adverse events (AEs) were pruritus (42%; 95% CI: 16-73; I ²=74%), fatigue (27%; 95% CI: 8-60; I ²=67%), and arthralgia (14%; 95% CI: 5-37; I ²=60%). This meta-analysis supports the antitumor activity of PD-1/PD-L1 inhibitors in KS. Despite high AE rates, most were clinically manageable.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"56-63"},"PeriodicalIF":2.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunoregulatory Cyclophilin A Reprograms the Tumor Immune Microenvironment by Changing the Activation and Exhaustion Profile of T Cells and NK Cells in the Model of Melanoma B16 in Vivo. 免疫调节性亲环蛋白A通过改变体内黑色素瘤B16模型中T细胞和NK细胞的激活和衰竭谱，重编程肿瘤免疫微环境

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-02-01 Epub Date: 2025-11-03 DOI: 10.1097/CJI.0000000000000586

Anastasiia Kalinina, Leila R Tilova, Dmitry Kazansky, Ludmila Khromykh

{"title":"Immunoregulatory Cyclophilin A Reprograms the Tumor Immune Microenvironment by Changing the Activation and Exhaustion Profile of T Cells and NK Cells in the Model of Melanoma B16 in Vivo.","authors":"Anastasiia Kalinina, Leila R Tilova, Dmitry Kazansky, Ludmila Khromykh","doi":"10.1097/CJI.0000000000000586","DOIUrl":"10.1097/CJI.0000000000000586","url":null,"abstract":"Cold tumors have an immunosuppressive microenvironment (TME) with weak infiltration of functionally active NK and T cells. Such tumors poorly respond to immunotherapies, and different combined approaches are investigated to reprogram cold tumors into hot ones and improve treatment efficacy. The search for novel immunostimulatory factors for the therapy of cold tumors is of particular clinical relevance. Previously, we showed the antitumor effects of recombinant human Cyclophilin A (rhCypA), an analog of proinflammatory secretory CypA, in experimental models in vivo and indicated it as a stimulator of the antitumor immune response and a modulator of the immune TME. In this study, the effect of rhCypA on the functionality of tumor-infiltrating NK and T cells was investigated using the melanoma B16 tumor model in vivo . After rhCypA treatment, T cells in the TME differently expressed the transcription factors Tbet and Eomes and the exhaustion markers PD-1, LAG-3, and TIM3. Tumors of rhCypA-dosed mice contained a higher proportion of activated CD4 + CD25 + T cells and CD8 + T cells with upregulated activation markers CD44 and CD25 and co-stimulatory CD28. Similarly, rhCypA upregulated PD-1, CTLA-4, and CD25 and downregulated exhaustion markers KLRG-1 and LAG-3 in tumor-infiltrating NK cells. After rhCypA treatment, melanoma B16 was actively infiltrated with CD8 + T cells and NK cells with increased perforin and granzyme B production and TNFα-producing CD4 + cells. Thus, rhCypA reprogrammed the immune tumor microenvironment by boosting the accumulation of functionally more active NK and T cells with the enhanced production of cytotoxic factors while modulating their dysfunction and weakening immunosuppression.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"45-55"},"PeriodicalIF":2.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145431445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients. 非小细胞肺癌患者中性粒细胞与淋巴细胞比值早期动态变化对预后的影响。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-02-01 Epub Date: 2025-11-26 DOI: 10.1097/CJI.0000000000000590

Xiaoyan Liu, Dongming Zhang, Haoran Zhang, Yuequan Shi, Jia Liu, Xiaoxing Gao, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang

{"title":"Prognostic Role of Early Dynamic Changes in Neutrophil-to-Lymphocyte Ratio of Nonsmall Cell Lung Cancer Patients.","authors":"Xiaoyan Liu, Dongming Zhang, Haoran Zhang, Yuequan Shi, Jia Liu, Xiaoxing Gao, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang","doi":"10.1097/CJI.0000000000000590","DOIUrl":"10.1097/CJI.0000000000000590","url":null,"abstract":"To explore the relationship between early dynamic changes in neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) and treatment outcomes of patients with advanced nonsmall cell lung cancer (NSCLC) undergoing immunotherapy, we retrospectively analyzed 217 advanced NSCLC patients who received immunotherapy. NLR and LMR at baseline and 3 weeks after initiation of treatment and changes of NLR and LMR were calculated. Univariate and multivariable COX regression analysis was applied to explore the predictors of overall survival (OS). One hundred six (48.8%) demonstrated an increase in NLR after 3 weeks of initiating treatment, while 111 (51.2%) displayed a decrease in NLR. Low pretreatment and post-treatment NLR levels (<5), high pretreatment and post-treatment LMR levels (≥4), reduction of post-treatment NLR and elevation of post-treatment LMR were associated with improved objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and OS. In multivariate regression analysis, the number of distant metastases, lines of immunotherapy, levels of pretreatment and post-treatment NLR and LMR were significantly associated with OS. We developed the \"NLML\" prognostic scoring system, which showed an area under the curve (AUC) of 0.775 (95% CI: 0.700-0.838, P <0.001) and reached its peak at 3 years (AUC=0.955, 95% CI: 0.909-0.982, P <0.001). Early dynamic alterations in NLR and LMR values from pre-treatment to post-treatment, along with individual pretreatment or post-treatment NLR or LMR levels, exhibited correlations with treatment outcomes in patients undergoing either mono-immunotherapy or chemoimmunotherapy. The \"NLML\" prognostic scoring system emerged as a practical and effective model for predicting survival within this patient population.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"64-73"},"PeriodicalIF":2.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145724033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis. IC-ICCRT-IO与CT-CCRT治疗不能切除的局部晚期ESCC的疗效和安全性比较：回顾性分析。

IF 2.9 4区医学

Journal of Immunotherapy Pub Date : 2026-02-01 Epub Date: 2025-09-08 DOI: 10.1097/CJI.0000000000000578

Ruifeng Wang, Tianhui Guo, Qi Wang, Wen Gao, Yimiao Yu, Jun Zhang, Wenqian Fu, Biyuan Zhang, Haiji Wang

{"title":"Comparing the Efficacy and Safety of IC-ICCRT-IO With CT-CCRT for Unresectable Locally Advanced ESCC: A Retrospective Analysis.","authors":"Ruifeng Wang, Tianhui Guo, Qi Wang, Wen Gao, Yimiao Yu, Jun Zhang, Wenqian Fu, Biyuan Zhang, Haiji Wang","doi":"10.1097/CJI.0000000000000578","DOIUrl":"10.1097/CJI.0000000000000578","url":null,"abstract":"The present study was designed to evaluate the efficacy and safety of induction chemotherapy combined with a PD-1 inhibitor (sintilimab) followed by concurrent chemoradiotherapy (CCRT) plus sintilimab and subsequent maintenance (IC-ICCRT-IO) in patients with unresectable locally advanced esophageal squamous carcinoma (ESCC) compared with induction chemotherapy followed by CCRT without PD-1 inhibitors (CT-CCRT) using propensity score matching (PSM). Data collected from patients with histologically confirmed, inoperable ESCC treated with IC-ICCRT-IO or CT-CCRT were retrospectively analyzed-a 1:1 PSM with a caliper of 0.05 balanced potential biases. Treatment effects and adverse events (AEs) were assessed using imaging, medical records, and follow-up. Primary endpoints were median progression-free survival (PFS) and PFS rates at 12 and 18 months. Secondary endpoints included overall survival (OS), response rates, and safety. The results showed that t he PSM produced 27 comparable pairs; the median follow-up was 20.5 months. IC-ICCRT-IO significantly improved PFS (median not reached, 12 mo rate: 96.6% vs. 80.5%; 18 mo rate: 85.2% vs. 63.0%, P =0.011) and OS (median not reached, 12 and 18 mo rate: 100% vs. 88.9%, P =0.007). Objective response rates were 88.9% versus 48.1% ( P =0.003). Grade ≥3 AEs occurred in 55.6% versus 44.4% ( P =0.586), primarily nonimmune-related. Severe immune-related rash and radiation pneumonitis were rare and manageable. The results suggested that IC-ICCRT-IO shows promise as an effective, safe treatment for unresectable, locally advanced ESCC. Prospective studies are needed to confirm these findings.","PeriodicalId":15996,"journal":{"name":"Journal of Immunotherapy","volume":" ","pages":"74-84"},"PeriodicalIF":2.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0